partly by parthanatos: a new view of how akt inhibitors kill cancer cells
Published 2 years ago • 124 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
1:19
relacorilant nab-paclitaxel in recurrent, platinum-resistant ovarian cancer
-
0:43
explore upa and pai-1 tests, crucial markers in understanding tumor progression. #upatest #pai1test
-
0:39
pathbreaking discovery human evolution and paleogenomics
-
2:33
new chemotherapy: bevacizumab & parp inhibitors | memorial sloan kettering
-
0:59
path to getting a diagnosis: pathology
-
1:14
biopsy analyses from the talave trial of induction talazoparib
-
1:57
dr. tripathy discusses the averel bevacizumab trial results
-
8:31
recent updates in prostate cancer: stampede, vision & profound
-
3:10
pioneer trial update: avapritinib for indolent systemic mastocytosis
-
3:43
startar: adt apalutamide rt docetaxel for psa-recurrent prostate cancer following rp
-
26:21
researchers show how sars-cov-2 spike protein causes acute lung injury in mice
-
1:19
the potential of caplacizumab in the treatment of attp
-
5:23
case of the week: portal vein aneurysm
-
8:42
progress report i - panagiotis paraskevopoulos
-
7:30
case 14 | pathologists online
-
1:00:52
understanding cancer lecture 8 pi3k/akt/mtor pathway normal and dysregulated
-
2:07
dr. eric p. winer on pathologic complete response and disease free survival in breast cancer
-
12:11
progress report iv - vivien unger
-
2:11
thoughts on panobinostat’s recent withdrawal from the us market